II-01 Khaled Abduljalil
Impact of OATP1B1 Polymorphism on Pravastatin Pharmacokinetics during Pregnancy; Physiologically Based Pharmacokinetic model Prediction
Wednesday 15:35-17:00 |
II-02 Tariq Abdulla
Using Simcyp Designer to extend a PBPK-QSP Model of Warfarin to Target Binding
Wednesday 15:35-17:00 |
II-03 Oliver Ackaert
Exposure Response Analysis of the Effect of Loperamide on the Cardiac Repolarization Interval in Healthy Adult Subjects
Wednesday 15:35-17:00 |
II-04 Eleni Alexopoulou
Population pharmacokinetics of budesonide (BDS) and its two main metabolites 6β-hydroxy-budesonide(6OH-BDS) and 16α-hydroxy-prednisolone(16OH-PREDN) with and without hyperhydration effect
Wednesday 15:35-17:00 |
II-05 Mahmoud Ali
Evaluation of the robustness of methods for model-based bioequivalence analysis for biosimilars: Clenoliximab as a case study
Wednesday 15:35-17:00 |
II-06 Simon Arsène
In silico trials platform for exploration of trial design space in atopic dermatitis
Wednesday 15:35-17:00 |
II-07 Peter Ashcroft
Mechanistic PKPD modelling of targeted protein degradation to improve compound selection in drug discovery and translation to the clinic
Wednesday 15:35-17:00 |
II-08 Rami Ayoun Alsoud
Model-based interspecies scaling and impact of anti-drug antibodies on the pharmacokinetics of the therapeutic protein CB 4332
Wednesday 15:35-17:00 |
II-09 Nicolas Azzopardi
Mechanistic model of oxytocin/vasopressin-stimulated GPCR.
Wednesday 15:35-17:00 |
II-10 Dana Bakir
Investigating Interoccasion Variability and Estimation Methods
Wednesday 15:35-17:00 |
II-11 Pavel Balazki
4ß-OH Cholesterol as endogenous biomarker for CYP3A4 inducer DDI studies – a PBPK-QSP platform for in silico compound testing
Wednesday 15:35-17:00 |
II-12 Catalina Barcelo
Use of informative prior distributions from mepolizumab data to support depemokimab PKPD model analysis
Wednesday 15:35-17:00 |
II-13 Roberta Bartolucci
Exposure-Response Analysis of the Macitentan Effects on NT-proBNP and WHO functional class in adult patients with Pulmonary Arterial Hypertension
Wednesday 15:35-17:00 |
II-14 Mattia Berton
Physiologically based pharmacokinetic modelling to investigate the impact of obesity on the pharmacokinetics of rilpivirine, efavirenz, and etravirine
Wednesday 15:35-17:00 |
II-15 Sara Bettonte
Onset and disappearance of induction on CYP3A4 and UGT1A1 substrates using PBPK modelling
Wednesday 15:35-17:00 |
II-16 Davide Bindellini
Understanding the physiology of the hypothalamic-pituitary-adrenal axis to optimise cortisol replacement therapy: A quantitative modelling framework
Wednesday 15:35-17:00 |
II-17 Peter Bloomingdale
An Artificial Intelligence Framework for Optimal Drug Design
Wednesday 15:35-17:00 |
II-18 Ivan Borisov
An Algorithm to Generate Virtual Patients Cohort for a Model of Solid Tumor Treatment
Wednesday 15:35-17:00 |
II-19 Rolien Bosch
Linking 4GI Glucose Homeostasis and Hall Body Composition Models to study GLP-1R Agonist effects on glucose and body weight
Wednesday 15:35-17:00 |
II-20 Thomas Bouillon
Comparison and selection of dosing regimens by discretization, optimizing efficacy and evaluating exposure demonstrated for KAE609 (Cipargamin)
Wednesday 15:35-17:00 |
II-21 THAM THI BUI
Development of a physiological-based pharmacokinetic model for sacubitril and its metabolite
Wednesday 15:35-17:00 |
II-22 Núria Buil Bruna
Understanding onset and extent of response using different clinical endpoints in Atopic Dermatitis
Wednesday 15:35-17:00 |
II-23 Elisa Calvier
PBPK modelling of the DDI between a Drug X and gemfibrozil
Wednesday 15:35-17:00 |
II-24 Simona Catozzi
Inter-species and in vitro-in vivo scaling for quantitative modeling of whole-body drug pharmacokinetics in patients: Application to the anticancer drug oxaliplatin
Wednesday 15:35-17:00 |
II-25 Geraldine Celliere
Comparison of a typical PK/PD model versus a mechanistic QSP model to predict the Phase II of a PSCK9 inhibitor, using MonolixSuite
Wednesday 15:35-17:00 |
II-26 JunSeok Cha
A Pharmacokinetic/Pharmacodynamic Model of Recombinant Batroxobin
Wednesday 15:35-17:00 |
II-27 Marylore Chenel
Physiologically based pharmacokinetic (PBPK) modeling of the oral absorption of 5-flucytosine to support further development of a sustained-release formulation for the treatment of cryptococcal meningoencephalitis
Wednesday 15:35-17:00 |
II-28 Wendy Chu
Disease-specific differences in pharmacokinetics of paromomycin and miltefosine between post-kala-azar dermal leishmaniasis and visceral leishmaniasis patients in Eastern Africa
Wednesday 15:35-17:00 |
II-29 Brian Cicali
Long-acting formulation drug-drug interactions: evaluating the importance of timing using a subcutaneous levonorgestrel PBPK example
Wednesday 15:35-17:00 |
II-30 Michael Cloesmeijer
Physiologically-based pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) and recombinant FIX (rFIX) to characterize extravasation and binding to type IV collagen
Wednesday 15:35-17:00 |
II-31 Aude Coumau
Population pharmacokinetic modelling to characterize (es)citalopram exposure in a large cohort of psychiatric patients
Wednesday 15:35-17:00 |
II-32 Jared Cui
Incorporating complex drug PK with multiple binding targets into a QSP model to predict combined PD effects
Wednesday 15:35-17:00 |
II-33 Marina Cuquerella Gilabert
Title: Development of a Compartmental Advanced Physiologically based Dissolution, Absorption and Transit (CA-PhysDAT) model in PhysPK
Wednesday 15:35-17:00 |
II-34 Anna Dari
Mechanistic Modeling Projections of Antibody Persistence After Homologous Booster Regimens of COVID-19 Vaccine Ad26.COV2.S in Humans
Wednesday 15:35-17:00 |
II-35 Pieter-Jan De Sutter
Comparison of monoclonal antibody disposition predictions between different PBPK platforms
Wednesday 15:35-17:00 |
II-36 Wilbert de Witte
Whole-body PBPK with tissue TMDD modelling to predict determining parameters of target occupancy in tissues
Wednesday 15:35-17:00 |
II-37 Neel Deferm
Development of a physiologically-based pharmacokinetic model of enzalutamide, a strong CYP3A4 inducer
Wednesday 15:35-17:00 |
II-38 Cleo Demeester
Implementation of Oral Drug Absorption in Older Adults in the Physiologically Based Pharmacokinetic (PBPK) Modelling Platforms
Wednesday 15:35-17:00 |
II-39 Abdallah Derbalah
Characterization of the hepatic distribution of oligonucleotide therapeutics using a cross-species biologics PBPK model
Wednesday 15:35-17:00 |
II-40 Qian Dong
Population pharmacokinetic analysis of nonlinear behavior of adefovir
Wednesday 15:35-17:00 |
II-41 Ilse Dubbelboer
Lactation related milk volume changes: implementation in a PBPK cow model for oxytetracycline
Wednesday 15:35-17:00 |
II-42 Janna Duong
A dermal physiologically-based pharmacokinetic (PBPK) model of clobetasol propionate to predict systemic exposure in eczema and dermatitis patients
Wednesday 15:35-17:00 |
II-43 Marwa Elhefnawy
Quantifying the rate of blood glucose changes over the acute stage of ischemic stroke among patients with diabetes.
Wednesday 15:35-17:00 |
II-44 Jacqueline Ernest
A translational site-of-action PK-PD modeling platform to propose treatment shortening regimens for tuberculosis
Wednesday 15:35-17:00 |
II-45 Edoardo Faggionato
Assessing insulin sensitivity, glucose effectiveness, and β-cell responsivity using an integrated glucose, insulin, and C-peptide minimal model
Wednesday 15:35-17:00 |
II-46 Undine Falkenhagen
Can quantitative systems pharmacology guide precision dosing? An illustrative warfarin-INR example
Wednesday 15:35-17:00 |
II-47 Alan Faraj
A model for evaluation of novel on-demand treatment of bleeding events in hemophilia subjects
Wednesday 15:35-17:00 |
II-48 Anna Fochesato
A minimal PBPK model to unveil anti-tuberculosis drug distribution in pulmonary lesions: a blueprint for improving efficacy screenings.
Wednesday 15:35-17:00 |
II-49 Sylvaine Galiegue
Derisking the development of rilzabrutinib, a BTK inhibitor currently in phase III, with a PBPK model in lieu of some clinical studies
Wednesday 15:35-17:00 |
II-50 María García-Cremades
Risk stratification algorithm for MDR-TB patients based on pooled individual data analysis.
Wednesday 15:35-17:00 |
II-51 Maite Garraza Obaldia
Semi-mechanistic model of the Haemodynamic effects of propofol and remifentanil administered in combination to patients undergoing general anaesthesia
Wednesday 15:35-17:00 |
II-52 Frédéric Gaspar
Population pharmacokinetics of apixaban in a real-life hospitalized population
Wednesday 15:35-17:00 |
II-53 Amira Ghoneim
Modeling of the Pharmacokinetics of the Selective Orexin-1 Receptor Antagonist ACT-539313 with Auto-Inhibition
Wednesday 15:35-17:00 |
II-54 Audrick GIBERT
PK/PD of unfractionned heparin during cardiopulmonary bypass: an individual patient data meta-analysis of two studies
Wednesday 15:35-17:00 |
II-55 Janice Goh
A translational toolkit to predict clinical Phase IIb/III outcomes from preclinical mouse studies
Wednesday 15:35-17:00 |
II-56 Benjamin Guiastrennec
Model-Based Translational Rapamycin Dose Selection to Promote Engraftment and Expansion of the Engineered Regulatory T cell (EngTreg) product GNTI-122 in Human
Wednesday 15:35-17:00 |
II-57 Berfin Gülave
P-glycoprotein mediated drug-drug interaction at the blood-brain barrier on morphine brain distribution
Wednesday 15:35-17:00 |
II-58 Andrea Guzmán
Individualized Tacrolimus dosing in pediatric kidney transplantation: identification of new genomic, proteomic and metabolomic biomarkers and PhysPK® development of PBPK-based predictive models, simulations and applications in different phamacogenomic subpopulations.
Wednesday 15:35-17:00 |
II-59 Sofia Guzzetti
An integrated modelling approach for targeted degradation: insights on optimisation, data requirements and PKPD predictions from semi- or fully-mechanistic models and exact steady state solutions
Wednesday 15:35-17:00 |
II-60 Chihiro Hasegawa
Exploring simplification of a target-mediated drug disposition (TMDD) model for bispecific antibodies for potential application to data-driven modelling
Wednesday 15:35-17:00 |
II-61 Sara Carolina Henriques
Development of a joint dissolution and pharmacokinetic model of propafenone and its hydroxylated metabolite
Wednesday 15:35-17:00 |
II-62 Yannick Hoffert
An automated multi-model selection algorithm to improve precision dosing of tacrolimus in liver, lung, and bowel transplant recipients
Wednesday 15:35-17:00 |
II-63 Ana Homšek
Population pharmacokinetic model of infliximab in patients with fistulising Crohn’s disease
Wednesday 15:35-17:00 |
II-64 Vincent Hurez
Development of a primary Sjogren’s Syndrome (pSS) quantitative systems pharmacology (QSP) model linking mechanistic pathways to clinical scores.
Wednesday 15:35-17:00 |
II-65 Manuel Ibarra
Enhancing the predictive accuracy of PBPK models for drug concentrations in tissues: accounting for the impact of relative distribution of blood flow
Wednesday 15:35-17:00 |
II-66 Vijay Ivaturi
Novel convolution-based In vitro-In vivo correlation (IVIVC) model with time scaling and bioavailability sub-models for, JORNAY PM®, a methylphenidate hydrochloride delayed-release and extended-release capsule
Wednesday 15:35-17:00 |
II-67 Nattapon Jaisupa
A physiologically-based pharmacokinetic model for prediction of cannabidiol pediatric dose
Wednesday 15:35-17:00 |
II-68 Masoud Jamei
Application of a PBPK Model to Predict the Required Ceftazidime Concentration and Duration in Maternal and Umbilical Plasma Prior to Caesarean Section in Virtual Pregnant Women with Different Renal Function
Wednesday 15:35-17:00 |
II-69 SEONGMEE JEONG
Human effective dose prediction of analgesic drug using translational PK-PD modeling
Wednesday 15:35-17:00 |
II-70 Woojin Jung
Fractal kinetic implementation in population modeling
Wednesday 15:35-17:00 |
II-71 Soo-Min Jung
Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis of Nesuparib (JPI-547) in Patients with Advanced Solid Tumor
Wednesday 15:35-17:00 |
II-72 Daniel Kaschek
Joint modeling with Monolix using IQR Tools
Wednesday 15:35-17:00 |
II-73 Atefeh Kazeroonian
A first-ever mechanistic disease model of IgG4-related disease identifies high-potential therapy targets
Wednesday 15:35-17:00 |
II-74 heungjo Kim
Population pharmacokinetics of intravenous midazolam in critically ill patients supported with extracorporeal membrane oxygenation therapy
Wednesday 15:35-17:00 |
II-75 Bastian Kister
Quantitative Systems Pharmacology of Interferon Alpha Administration and its induced cellular response in mice
Wednesday 15:35-17:00 |
II-76 Christine Juliane Kleist
A PKPD model of favipiravir and ribavirin in Lassa virus infected mice
Wednesday 15:35-17:00 |
II-77 Niklas Korsbo
DeepPumas for automatic discovery of individualizable functions governing longitudinal patient outcomes
Wednesday 15:35-17:00 |
II-78 Anis Krache
Modelling selective cell targeting through avidity to inform bispecific antibody discovery and development
Wednesday 15:35-17:00 |
II-79 Hanna Kunina
Blood glucose profile evaluation with model-based approach using continuous glucose monitoring data
Wednesday 15:35-17:00 |
II-80 Jialin Mao
Shared Learning from a Physiologically-Based Pharmacokinetic Modeling Strategy for Human Pharmacokinetics Prediction through Retrospective Analysis of Genentech Compounds
Wednesday 15:35-17:00 |
II-81 Francois Mercier
Bridging the gap between two-stage and joint models: The case of tumor growth inhibition and overall survival models
Wednesday 15:35-17:00 |
II-82 Andreas Noack
On the error of the Laplace approximation when lags and duration parameters have between-subject variation
Wednesday 15:35-17:00 |
II-83 Rune Overgaard
Similar efficacy and gastrointestinal tolerability versus exposure for oral and subcutaneous semaglutide
Wednesday 15:35-17:00 |
II-84 Teun Post
Innovative adaptive dose simulations in NONMEM to allow simulation-based model evaluation of titration-based dosing, applied to a population dose-hemoglobin model for Jesduvroq (daprodustat)
Wednesday 15:35-17:00 |
II-85 Mar Ribera I Armengol
Application of Structural Identifiability Analysis and Parametrisation of a Linear Mixed Effects Mirabegron Model
Wednesday 15:35-17:00 |
II-86 Elena Righetti
A mechanistic model of α-synuclein aggregation and degradation to bridge in vitro and in vivo research on Parkinson’s disease.
Wednesday 15:35-17:00 |
II-87 Sergio Sánchez Herrero
Integrating Python optimization algorithms inside PhysPK® (PK/PD/PBPK) software for improving PK estimation methods.
Wednesday 15:35-17:00 |
II-88 Rajendra Singh
A Time-to-event Modeling Approach Supporting the Safety Profile of New Deutetrabenazine (AUSTEDO) Titration Schemes in Patients with Tardive Dyskinesia and Huntington’s Disease
Wednesday 15:35-17:00 |
II-89 Nelleke Snelder
From glomerular filtration rate to renal composite endpoint: an integrated time-to-event analysis of finerenone in phase 3 studies.
Wednesday 15:35-17:00 |
II-90 Sara Soufsaf
An Exploratory Analysis of the Performance of Methylphenidate Regimens Based on a PKPD Model of Dopamine and Norepinephrine Transporter Occupancy
Wednesday 15:35-17:00 |
II-91 Britta Steffens
Enhanced pharmacometrics model utilizes heart rate to monitor thyroid function in pediatric Graves’ disease under pharmacotherapy
Wednesday 15:35-17:00 |
II-92 Mohamed Tarek
Marginal No-U-Turn Sampler for Bayesian Analysis in Pharmacometrics
Wednesday 15:35-17:00 |
II-93 Mohamed Tarek
Fast cross-validation for Bayesian inference using proposals on a linear subspace
Wednesday 15:35-17:00 |
II-94 Franziska Thoma
A fully hierarchical Bayesian approach to sequentially update population parameter uncertainty in MIPD
Wednesday 15:35-17:00 |
II-95 Monika Twarogowska
A method to correct VPC bias due to non-random dropout via censored data addition, using the MonolixSuite
Wednesday 15:35-17:00 |
II-96 Martijn van Noort
Two new user-friendly approaches to assess pharmacometric model identifiability
Wednesday 15:35-17:00 |
II-97 Yanlin Wang
Development of a Population Pharmacokinetic Model to Describe the Pharmacokinetics of Aripiprazole 2-Month Ready-to-Use, a Novel Long-Acting Injectable Formulation of Aripiprazole for Administration Once Every 2 Months
Wednesday 15:35-17:00 |
II-98 Jen-Hao (Eric) Wu
Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia – results of study ITCC-059
Wednesday 15:35-17:00 |
